EUVIMEDEUVIMED entdecken
Open Access

Targeting platinum-resistant ovarian cancer by disrupting histone and RAD51 lactylation

Chenggong Sun, Xiao Li, Qiuli Teng, Xihan Liu, Li Song, Helgi B Schiöth, Huan Wu, Xinyue Ma, Zhaoyang Zhang, Changjian Qi, Haocheng Zhang, Kun Song und 2 weitere

Theranostics · 10.02.2025 · 15 (7) · 3055-3075

DOI: 10.7150/thno.104858 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, erschienen am 10.02.2025. Verfasst von Chenggong Sun und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, PR China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Drug Resistance, Neoplasm, Histones, Rad51 Recombinase. Die Arbeit wurde bisher 97-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsDrug Resistance, NeoplasmHistonesRad51 RecombinaseFemaleHumansAnimalsMiceCisplatinCell Line, TumorXenograft Model Antitumor AssaysAntineoplastic AgentsGene Expression Regulation, NeoplasticMice, NudePlatinum

Stichwörter der Autor:innen

HR repairRAD51lactylationovarian cancerplatinum resistance

Substanzen

HistonesRad51 RecombinaseCisplatinRAD51 protein, humanAntineoplastic AgentsPlatinum

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, PR China.
  • Gynecology Oncology Key Laboratory, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, PR China.
  • Division of Gynecology Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, PR China.
  • Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, 751 24 Uppsala, Sweden.

Zitieren

APA

Sun, C., Li, X., Teng, Q., Liu, X., Song, L., Schiöth, H. B., Wu, H., Ma, X., Zhang, Z., Qi, C., Zhang, H., Song, K., Zhang, Q., & Kong, B. (2025). Targeting platinum-resistant ovarian cancer by disrupting histone and RAD51 lactylation. Theranostics, 15(7), 3055-3075. https://doi.org/10.7150/thno.104858

Vancouver

Sun C, Li X, Teng Q, Liu X, Song L, Schiöth HB, et al. Targeting platinum-resistant ovarian cancer by disrupting histone and RAD51 lactylation. Theranostics. 2025;15(7):3055-3075. doi:10.7150/thno.104858

BibTeX
@article{Sun2025,
  author = {Sun, Chenggong and Li, Xiao and Teng, Qiuli and Liu, Xihan and Song, Li and Schiöth, Helgi B and Wu, Huan and Ma, Xinyue and Zhang, Zhaoyang and Qi, Changjian and Zhang, Haocheng and Song, Kun and Zhang, Qing and Kong, Beihua},
  title = {Targeting platinum-resistant ovarian cancer by disrupting histone and RAD51 lactylation},
  journal = {Theranostics},
  year = {2025},
  volume = {15},
  number = {7},
  pages = {3055--3075},
  doi = {10.7150/thno.104858}
}
Kostenlos starten →